Facility Evaluation Report

Licensing Program Analyst (LPA) Alvaro Ramirez, Jr made an unannounced case management visit in conjunction with Unusual Incident/Injury Report (UIIR) dated August 27, 2025. LPA was greeted and granted entry by Executive Director (ED) Krista Solomon. LPA explained the reason for the visit.

Per UIIR during the morning of August 25, 2025, Resident 1 (R1) was given two doses of amlodipine, levothyroxine, and vitamin D3.

During today's visit LPA reviewed the Physician's orders dated September 10, 2025, for R1. Per Physician's orders R1 is prescribed Amlodipine Besylate 5 mg, one tablet by mouth twice daily. Per Physician's orders R1 is prescribed levothyroxine Sodium 100 mcg, one tablet by mouth daily. Per Physician's orders R1 is prescribed vitamin D3, 25 mcg, one tablet by mouth daily.

A Health and Safety inspection was conducted, and LPA Ramirez observed no Health and Safety concerns during today's visit.

Based on observations and records reviewed during today’s inspection, one deficiency is being cited per Title 22 Division 6 of the California Code of Regulations. An exit interview was conducted with ED Solomon and a copy of this report and Appeal Rights were provided at the time of exit.